Dr. Miron on the treatment of intraductal carcinoma of the prostate

In this video Benjamin Miron, MD, a medical oncologist at Fox Chase Cancer Center, discusses the diagnosis and treatment of patients with intraductal carcinoma of the prostate. The National Cancer Institute defines intraductal carcinoma of the prostate as a cancer that usually starts in “the glandular (secretory) tissue that lines the prostate and spreads to the ducts within the prostate.”¹

At the 2023 ASCO Annual Meeting, Miron shared an abstract entitled, “Clinical implications of molecular alterations in intraductal carcinoma of the prostate.”²

Transcript

Intraductal carcinoma of the prostate is a pathologic diagnosis. So, the pathologist is going to be looking at the slides and identify that there are prostate cancer cells within the ducts of the prostate. So it's something that they identify after potentially a biopsy, or the prostate is removed. And I think for now, we're managing these patients similarly, but you might note that the patients who have this finding tend to have larger tumors and that might impact your decision-making individually upfront. But for now, we do still treat intraductal carcinomas of the prostate as a standard of care, just with the caveat that these are high-risk patients and they do have a high likelihood of having advanced or metastatic disease in the future.

Transcript has been edited for clarity.

References

1. National Cancer Institute. Intraductal prostate carcinoma. Accessed June 19, 2023. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/intraductal-prostate-carcinoma

2. Miron B, Wei S, Yasmine B, et al. Clinical implications of molecular alterations in intraductal carcinoma of the prostate. J Clin Oncol 41, no. 16_suppl (June 01, 2023) 5024-5024. doi: 10.1200/JCO.2023.41.16_suppl.5024